Stefan Symeonides
Senior Clinical Lecturer in Medical Oncology
- Cancer Research UK Edinburgh Centre
- MRC Institute of Genetics & Molecular Medicine
- Western General Hospital - NHS Lothian
Contact details
- Tel: +44 (0)131 651 8500
- Email: Stefan.Symeonides@ed.ac.uk
Address
- Street
-
Cancer Research UK Edinburgh Centre
MRC Institute of Genetics & Molecular Medicine
The University of Edinburgh
Western General Hospital
Crewe Road South - City
- Edinburgh
- Post code
- EH4 2XR
- Street
-
Western General Hospital
Crewe Road South - City
- Edinburgh
- Post code
- EH4 2XU
Background
Stefan Symeonides is a Medical Oncologist and Senior Lecturer in Experimental Cancer Medicine at the Edinburgh Cancer Research Centre and at the linked Edinburgh Cancer Centre (NHS Lothian). After clinical training in the UK (Cambridge & Edinburgh), Australia (Melbourne) & New Zealand (Christchurch), and research in academia (Cambridge & Edinburgh), clinic (Edinburgh) and industry (AstraZeneca, various UK Biotechs), he is currently in a CSO Clinician Scientist Fellowship and leads bridging the space between pre-clinical and clinical cancer drug development in Edinburgh, linking laboratory and clinical research.
In the clinic, he leads the Phase I Trials Unit and also has a specialty focus on renal cancers within the Uro-oncology team. He leads a growing portfolio of early phase trials and also continues in drug development, working with CRUK’s Centre for Drug Development and in an advisory role for a number of UK Biotechs.
His research focus is on novel therapeutic discovery and development. Although he works across cytotoxic, small molecule, metabolic and even psychological therapies, his main focus is immunotherapies and he is the clinical lead for the Edinburgh Cancer Immunology Research Network. He is particularly interested in combining cancer immunotherapies to improve their activity. His current FAK-PD1 trial (NCT02758587) of combination PD-1 (pembrolizumab) and FAK (defactinib) inhibition is an example of how scientific discoveries at the Edinburgh Cancer Research Centre (Serrells et al, Cell 2015) are being translated into the clinic (running in centres UK-wide across the Experimental Cancer Medicine Centre network), while maintaining the link with ongoing laboratory work to refine and optimise treatment.
-
The immunopeptidome from a genomic perspective: Establishing the noncanonical landscape of MHC class I–associated peptides
(39 pages)
In:
Cancer Immunology Research, pp. 1-40
DOI: https://doi.org/10.1158/2326-6066.CIR-22-0621
Research output: Contribution to Journal › Article (E-pub ahead of print) -
Project Optimus, an FDA initiative: considerations for cancer drug development internationally, from an academic perspective
In:
Frontiers in Oncology
DOI: https://doi.org/10.3389/fonc.2023.1144056
Research output: Contribution to Journal › Article (Published) -
ARomatase Inhibition plus/minus Src-inhibitor SaracaTinib (AZD0530) in Advanced breast CAncer Therapy (ARISTACAT): a randomised phase II study
In:
Breast cancer research and treatment
DOI: https://doi.org/10.1007/s10549-023-06873-8
Research output: Contribution to Journal › Article (Published) -
Initial active surveillance for patients with metastatic renal cell carcinoma: 10 years' experience at a regional cancer Centre
In:
Cancer Medicine
DOI: https://doi.org/10.1002/cam4.5330
Research output: Contribution to Journal › Article (Published) -
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
In:
The Lancet Oncology, vol. 23, pp. 1133-1144
DOI: https://doi.org/10.1016/S1470-2045(22)00487-9
Research output: Contribution to Journal › Article (Published)